Login to Your Account

Neovacs Testing European IPO Market; Seeks €20M for RA Trials

By Jennifer Boggs

Monday, March 22, 2010

Hoping to follow the one Australian and three U.S. biotechs that have managed to go public this year, French immunotherapy firm Neovacs SA is seeking to raise about €20 million (US$27 million) and boost its profile with a listing on the Alternext Exchange in Paris. (BioWorld Today)


Assistant Managing Editor


To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription